Home
SGMT
SGMT News

Latest Sagimet Biosciences Inc. Series A (SGMT) News on October 30, 2025

MT Newswires

6 days ago

Sector Update: Health Care Stocks Edge Higher Late Afternoon

MT Newswires

6 days ago

Sector Update: Health Care

MT Newswires

6 days ago

Sagimet Shares Rise After Denifanstat Meets All Endpoints in Phase 3 Acne Trial

Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference

GlobeNewswire

6 days ago

Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference

All You Need to Know About Sagimet Biosciences Inc. (SGMT) Rating Upgrade to Strong Buy

Zacks

15 days ago

All You Need to Know About Sagimet Biosciences Inc. (SGMT) Rating Upgrade to Strong Buy

Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences

GlobeNewswire

16 days ago

Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences

Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025

GlobeNewswire

23 days ago

Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025

Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit

GlobeNewswire

2 months ago

Sagimet Biosciences Announces Upcoming Presentations at 9th Annual MASH Drug Development Summit

We Think Sagimet Biosciences (NASDAQ:SGMT) Can Afford To Drive Business Growth

Simply Wall St.

3 months ago

We Think Sagimet Biosciences (NASDAQ:SGMT) Can Afford To Drive Business Growth

What Makes Sagimet Biosciences Inc. (SGMT) a Strong Momentum Stock: Buy Now?

Zacks

5 months ago

What Makes Sagimet Biosciences Inc. (SGMT) a Strong Momentum Stock: Buy Now?

Wall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's What You Should Know

Zacks

5 months ago

Wall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's What You Should Know

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025

GlobeNewswire

5 months ago

Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025

Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update

BioPharma Dive

5 months ago

Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update

Uncovering Hidden Gems: Penny Stocks To Consider In June 2025

Simply Wall St.

5 months ago

Uncovering Hidden Gems: Penny Stocks To Consider In June 2025

MT Newswires

5 months ago

Sector Update: Health Care Stocks Advance Late Afternoon

MT Newswires

5 months ago

Sector Update: Health Care Stocks Advance in Afternoon Trading

MT Newswires

5 months ago

Sector Update: Health Care Stocks Mixed Premarket Wednesday

MT Newswires

5 months ago

Sector Update: Health Care

Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Trial In China, Stock Jumps

Benzinga

5 months ago

Sagimet's Partner Achieves Positive Results With Oral Acne Drug In Phase 3 Trial In China, Stock Jumps

MT Newswires

5 months ago

Sagimet Biosciences Says Acne Vulgaris Treatment Meets Phase 3 Trial Primary, Secondary Endpoints

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis

GlobeNewswire

5 months ago

Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis

Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025

GlobeNewswire

5 months ago

Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025

Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

GlobeNewswire

6 months ago

Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Top Penny Stocks To Watch In April 2025

Simply Wall St.

6 months ago

Top Penny Stocks To Watch In April 2025

Sagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025

GlobeNewswire

6 months ago

Sagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025

Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates

GlobeNewswire

8 months ago

Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates

MT Newswires

8 months ago

Sagimet Reports Acne Drug Candidate Cleared for Clinical Trials

Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne

GlobeNewswire

8 months ago

Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne

Is Sagimet Biosciences Inc. (SGMT) the Best Get Rich Quick Stock to Invest In?

Insider Monkey

8 months ago

Is Sagimet Biosciences Inc. (SGMT) the Best Get Rich Quick Stock to Invest In?

Sagimet Biosciences Inc. (SGMT): Among the Hot Penny Stocks to Buy Now

Insider Monkey

8 months ago

Sagimet Biosciences Inc. (SGMT): Among the Hot Penny Stocks to Buy Now

Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium

GlobeNewswire

8 months ago

Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium

US Penny Stocks Spotlight: Gevo And 2 Other Promising Picks

Simply Wall St.

9 months ago

US Penny Stocks Spotlight: Gevo And 2 Other Promising Picks

Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference

GlobeNewswire

10 months ago

Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference

Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.

10 months ago

Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans

Oppenheimer Predicts Up to ~580% Jump for These 2 ‘Strong Buy’ Stocks

TipRanks

a year ago

Oppenheimer Predicts Up to ~580% Jump for These 2 ‘Strong Buy’ Stocks

Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference

GlobeNewswire

a year ago

Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference

Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024

GlobeNewswire

a year ago

Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024

Institutional investors in Sagimet Biosciences Inc. (NASDAQ:SGMT) see US$36m decrease in market cap last week, although long-term gains have benefitted them.

Simply Wall St.

a year ago

Institutional investors in Sagimet Biosciences Inc. (NASDAQ:SGMT) see US$36m decrease in market cap last week, although long-term gains have benefitted them.

Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

GlobeNewswire

a year ago

Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Sagimet Biosciences to Participate in the UBS Global Healthcare Conference

GlobeNewswire

a year ago

Sagimet Biosciences to Participate in the UBS Global Healthcare Conference

Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024

GlobeNewswire

a year ago

Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024

Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024

GlobeNewswire

a year ago

Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology

GlobeNewswire

a year ago

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology

Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH

GlobeNewswire

a year ago

Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH

Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit

GlobeNewswire

a year ago

Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

GlobeNewswire

a year ago

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

GlobeNewswire

a year ago

Sagimet Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

GlobeNewswire

a year ago

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.

a year ago

Sagimet Biosciences (NASDAQ:SGMT) Is In A Good Position To Deliver On Growth Plans

NexTech Solutions Has Agreed to Acquire Rome Research Corporation to Expand Service Offerings and Enhance Mission Support Capabilities

PR Newswire

a year ago

NexTech Solutions Has Agreed to Acquire Rome Research Corporation to Expand Service Offerings and Enhance Mission Support Capabilities

Enhancing the Power of PTZs: Canon Announces New PTZ Firmware Updates Lending Greater Control and Operability, Including an Auto-Tracking Lite Version on Compatible PTZ Models*

GlobeNewswire

a year ago

Enhancing the Power of PTZs: Canon Announces New PTZ Firmware Updates Lending Greater Control and Operability, Including an Auto-Tracking Lite Version on Compatible PTZ Models*

Business Wire

a year ago

Form 8.3 - Darktrace plc

Business Wire

a year ago

Form 8.3 - International Distribution Services plc

US Supreme Court rejects Kroger challenge to Grubhub trademark win

Reuters

a year ago

US Supreme Court rejects Kroger challenge to Grubhub trademark win

Dow Jones Falls As AMD Slides On Downgrade; Nvidia Stock Split Takes Effect

Investor's Business Daily

a year ago

Dow Jones Falls As AMD Slides On Downgrade; Nvidia Stock Split Takes Effect

GlobeNewswire

a year ago

Middlefield Canadian Income PCC: Net Asset Value(s)

GoldATM Supports Growing Consumer Demand for Gold Purchase with New ATMs in North Carolina

Business Wire

a year ago

GoldATM Supports Growing Consumer Demand for Gold Purchase with New ATMs in North Carolina

Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat

GlobeNewswire

a year ago

Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

GlobeNewswire

a year ago

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024

GlobeNewswire

a year ago

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

GlobeNewswire

a year ago

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024

GlobeNewswire

a year ago

Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

GlobeNewswire

a year ago

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024

GlobeNewswire

2 years ago

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024

Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

GlobeNewswire

2 years ago

Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

GlobeNewswire

2 years ago

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

GlobeNewswire

2 years ago

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

GlobeNewswire

2 years ago

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

Blackstone and Other Asset Manager Stocks Have Soared. Earnings Shouldn’t Disappoint.

Barrons.com

2 years ago

Blackstone and Other Asset Manager Stocks Have Soared. Earnings Shouldn’t Disappoint.

Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock

GlobeNewswire

2 years ago

Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock

Chuck Royce Reduces Stake in NVE Corp

GuruFocus.com

2 years ago

Chuck Royce Reduces Stake in NVE Corp

Associated Press Finance

2 years ago

Essa Bancorp: Fiscal Q1 Earnings Snapshot

ESSA Bancorp, Inc. Announces Fiscal First Quarter 2024 Financial Results

ACCESSWIRE

2 years ago

ESSA Bancorp, Inc. Announces Fiscal First Quarter 2024 Financial Results

ON24 Unveils its Next Generation Platform, Unleashing a New Era of AI-powered Intelligent Engagement

Business Wire

2 years ago

ON24 Unveils its Next Generation Platform, Unleashing a New Era of AI-powered Intelligent Engagement

Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock

GlobeNewswire

2 years ago

Sagimet Biosciences Announces Proposed Public Offering of Series A Common Stock

Redwire Selected as Strategic Supplier for Blue Origin’s Trailblazing Blue Ring Space Mobility Platform

Business Wire

2 years ago

Redwire Selected as Strategic Supplier for Blue Origin’s Trailblazing Blue Ring Space Mobility Platform

Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

GlobeNewswire

2 years ago

Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH

EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND's Dividend Analysis

GuruFocus.com

2 years ago

EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND's Dividend Analysis

5 Stocks to Gain From Healthy End-of-Year Retail Sales

Zacks

2 years ago

5 Stocks to Gain From Healthy End-of-Year Retail Sales

A Look Back at Specialty Retail Stocks' Q3 Earnings: Petco (NASDAQ:WOOF) Vs The Rest Of The Pack

StockStory

2 years ago

A Look Back at Specialty Retail Stocks' Q3 Earnings: Petco (NASDAQ:WOOF) Vs The Rest Of The Pack

MoneyLion Inc. (ML) Is a Great Choice for 'Trend' Investors, Here's Why

Zacks

2 years ago

MoneyLion Inc. (ML) Is a Great Choice for 'Trend' Investors, Here's Why

Market Exclusive

2 years ago

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

SmartFinancial Sets Dates for Fourth Quarter Earnings Release and Conference Call

GlobeNewswire

2 years ago

SmartFinancial Sets Dates for Fourth Quarter Earnings Release and Conference Call

Trinity Capital Inc. Appoints Michael Testa as Chief Financial Officer

PR Newswire

2 years ago

Trinity Capital Inc. Appoints Michael Testa as Chief Financial Officer

Ecstasy-for-Medicine Advocate Raises $100 Million

The Wall Street Journal

2 years ago

Ecstasy-for-Medicine Advocate Raises $100 Million

If EPS Growth Is Important To You, Business First Bancshares (NASDAQ:BFST) Presents An Opportunity

Simply Wall St.

2 years ago

If EPS Growth Is Important To You, Business First Bancshares (NASDAQ:BFST) Presents An Opportunity

Rigetti Announces Public Availability of Ankaa-2 System with a 2.5x Performance Improvement Compared to Previous QPUs

GlobeNewswire

2 years ago

Rigetti Announces Public Availability of Ankaa-2 System with a 2.5x Performance Improvement Compared to Previous QPUs

The 3 Hottest Quantum Computing Stocks to Watch in 2024

InvestorPlace

2 years ago

The 3 Hottest Quantum Computing Stocks to Watch in 2024

RiverNorth Closed-End Funds Declare Monthly Distributions

Business Wire

2 years ago

RiverNorth Closed-End Funds Declare Monthly Distributions

Does Marine Products (NYSE:MPX) Deserve A Spot On Your Watchlist?

Simply Wall St.

2 years ago

Does Marine Products (NYSE:MPX) Deserve A Spot On Your Watchlist?

Village Super Market (NASDAQ:VLGE.A) Is Paying Out A Dividend Of $0.25

Simply Wall St.

2 years ago

Village Super Market (NASDAQ:VLGE.A) Is Paying Out A Dividend Of $0.25

FuelCell Energy (FCEL) Reports Q4 Earnings: What Key Metrics Have to Say

Zacks

2 years ago

FuelCell Energy (FCEL) Reports Q4 Earnings: What Key Metrics Have to Say

Pioneer Closed End Funds Required Notice to Shareholders Sources of Distribution Under Section 19(a)

Business Wire

2 years ago

Pioneer Closed End Funds Required Notice to Shareholders Sources of Distribution Under Section 19(a)

Acme United Corporation Board Increases Cash Dividend 7 Percent To $0.15 Per Share

GlobeNewswire

2 years ago

Acme United Corporation Board Increases Cash Dividend 7 Percent To $0.15 Per Share

An Intrinsic Calculation For Unisys Corporation (NYSE:UIS) Suggests It's 44% Undervalued

Simply Wall St.

2 years ago

An Intrinsic Calculation For Unisys Corporation (NYSE:UIS) Suggests It's 44% Undervalued

Sidoti Events, LLC's Virtual December Small-Cap Conference

ACCESSWIRE

2 years ago

Sidoti Events, LLC's Virtual December Small-Cap Conference

Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic

GlobeNewswire

2 years ago

Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic

Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit

GlobeNewswire

2 years ago

Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit

SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors

GlobeNewswire

2 years ago

SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors

Share on Social Networks: